%fl\$#flZflZ\$# \$\Z#\$#°`""ı "\L!(&__\\/__\)



annual, fiscal 2019 to present

`(#fi(ŁžłŁ`	2)23 ^{7,}	2022	2021	2020	2019
GAAP diluted earnings per share from continuing operations	\$	8.94 \$	5.98	\$ 14.10 \$	8.64 \$	6.34
Adjustments						
Gain on Dermstore Sale	\$	- \$	_	\$ (0.55) \$	- \$	_
Loss on debt extinguishment		_	_	_	0.75	0.01
Loss on investment '8,		_	_	_	0.03	0.06
Other '9,		_	0.03	0.01	0.04	(0.02
Other income tax matters *-		_	_	_	(0.04)	_
Adjusted diluted earnings per share from continuing operations	\$	8.94 \$	6.02	\$ 13.56 \$	9.42 \$	6.39

Note: Amounts may not foot due to rounding.

3DJ 69, &47G; I H) DCHDA? 7I; : +1C7C9?/A3I7I; B; CIH7H-&A; L ?> I>; 5/3/3; 9J CI? H7C; *M9>7C=;) DB B ?HDC/

^{7. +}ff ž 9DO-H;: D<! ž L;; @H9DB E7G: L ?>!+ L;; @H?C!>; 9DB E7G'8A E; GD: HEG H Q;:/

^{2 2;} EG H CHADH HDCDJGOK HB; CLC) 7H2; G3A; E',C9Y L>?9> L 7HCDL9DG ID DJG9DCLOC DE; G/LDCH/6; HDA I>2HOX HB; CLC 4DJG> FJ70; GLf1 fV

⁹ 11>: G1: B HJ CG A1:: ID 91 G6 C1 E: G1D: DE: G1/D0H CDC: D<L>9> L: G 3C: X? J7ANH≥CX97C1/

^{🧦 2;} EG H CHB; C; ∢H-COB I>; G HD4I1DC D<9; G77C 7C9DB; 17MB 7II; G-IJ CG; ATI;: ID 9J CG; CI E; CD; DE; C71 DCH/



7. +DJG> FJ7G; GI fl Ž 9DCHH;: D<±ž L;; @H9DB E7G; L 1> ±Ž L;; @H9Cl>; 9DB E7G*8A E; GD: HEG H G;:/

^{2 2;} EG H OH "=710H FMDH; HDC DIGTOK; HB; O TC) 71-E; G3A; E ",C9' L >9> L 7HODI 9DG ID DIG9DOTC! TC= DE; G1/DDH; 6; HDA I>1H70K; HB; O TC DIGO> FJ 70; GI fil fV

^{11&}gt;; G1; B H J G6; Al; : ID 9 G6; G1; GD; DE; G1/DCH CDC; DL > 3> L; G 7: 17/MIH=C28970/ 2; EGH GH '8; C &H fi; Mi; CH H 40B I>; GHDM1/DCD<9; G7/C709DB; 17/MB 7II; GH J G6; AI; : ID 91 G6; GE; CD: DE; G1/DCH/